Center-Authored Papers

Filters: Author is Crowley, John  [Clear All Filters]
2008
Goldman B, LeBlanc M, Crowley J.  2008.  Interim futility analysis with intermediate endpoints.. Clinical trials (London, England). 5(1):14-22. Abstract
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond KA, Bramwell VHC, Baker LH, Maki RG et al..  2008.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(4):626-32. Abstract
Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley J, Gandara DR.  2008.  Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(3):463-7. Abstract
Hoering A, LeBlanc M, Crowley J.  2008.  Randomized phase III clinical trial designs for targeted agents.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(14):4358-67. Abstract
Sculier J-P, Chansky K, Crowley J, Van Meerbeeck J, Goldstraw P.  2008.  The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 3(5):457-66. Abstract
Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DHM, Crowley J, Gandara DR.  2008.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(15):2450-6. Abstract
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le Q-T, Crowley J, Gandara DR.  2008.  Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(29):4771-6. Abstract
Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley J et al..  2008.  Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 3(9):1026-31. Abstract
2009
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP et al..  2009.  International prognostic scoring system for Waldenstrom macroglobulinemia.. Blood. 113(18):4163-70. Abstract
Hoering A, Crowley J, Shaughnessy JD, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E et al..  2009.  Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.. Blood. 114(7):1299-305. Abstract
Rami-Porta R, Crowley J, Goldstraw P.  2009.  The revised TNM staging system for lung cancer.. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia. 15(1):4-9. Abstract
Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR.  2009.  Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 4(1):87-92. Abstract
Dhodapkar MV, Hoering A, Gertz MA, Rivkin S, Szymonifka J, Crowley J, Barlogie B.  2009.  Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.. Blood. 113(4):793-6. Abstract
Lippman SM, Klein EA, Goodman PJ, Lucia SM, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano MJ, Hartline JA et al..  2009.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. JAMA : the journal of the American Medical Association. 301(1):39-51. Abstract
Chansky K, Sculier J-P, Crowley J, Giroux D, Van Meerbeeck J, Goldstraw P.  2009.  The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 4(7):792-801. Abstract
LeBlanc M, Rankin C, Crowley J.  2009.  Multiple Histology Phase II Trials.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(13):4256-62. Abstract
Albain KS, Unger JM, Crowley J, Coltman CA, Hershman DL.  2009.  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.. Journal of the National Cancer Institute. 101(14):984-92. Abstract
Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK et al..  2009.  Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(21):3540-6. Abstract
Hussein MA, Bolejack V, Zonder JA, Durie BGM, Jakubowiak AJ, Crowley J, Barlogie B.  2009.  Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(21):3510-7. Abstract
Zhou Y, Nair B, Shaughnessy JD, Cartron M-A, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B.  2009.  Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.. British journal of haematology. 145(5):637-41. Abstract
Le Q-TX, Moon J, Redman MW, Williamson SK, Lara PN, Goldberg Z, Gaspar LE, Crowley J, Moore DF, Gandara DR.  2009.  Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(18):3014-9. Abstract
Rubinstein L, Crowley J, Ivy P, LeBlanc M, Sargent D.  2009.  Randomized phase II designs.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(6):1883-90. Abstract
Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler PJ, Dakhil SR et al..  2009.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2530-5. Abstract
Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Epstein J, Crowley J et al..  2009.  TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.. British journal of haematology. 147(3):347-51. Abstract
Durie BGM, Van Ness B, Ramos C, Stephens O, Haznadar M, Hoering A, Haessler J, Katz MS, Mundy GR, Kyle RA et al..  2009.  Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(10):1913-9. Abstract